- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06550882
Um estudo de OBIZUR em adultos com hemofilia A adquirida (AHA) na Coreia do Sul
Vigilância pós-comercialização (vigilância de resultado de uso) da injeção de OBIZUR [Susoctocog Alpha (fator VIII anti-hemofílico suíno, recombinante)] para as indicações aprovadas na Coreia do Sul
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.
The main aim of the study is to learn how safe OBIZUR is in adults with AHA.
Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.
The treatment of the participants will be determined by the treating physicians.
During the study, data already existing in the participants' medical record and new data will be collected.
Visão geral do estudo
Descrição detalhada
This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Takeda Contact
- Número de telefone: +1-877-825-3327
- E-mail: medinfoUS@takeda.com
Locais de estudo
-
-
-
Seoul, Coréia do Sul, 06591
- Recrutamento
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Contato:
- Site Contact
- Número de telefone: +82-2-2258-5745
- E-mail: royoon@catholic.ac.kr
-
Investigador principal:
- Jae-ho Yoon
-
Seoul, Coréia do Sul, 05278
- Recrutamento
- Kyung Hee University Hospital at Gangdong
-
Contato:
- Site contact
- E-mail: pysped@khu.ac.kr
-
Investigador principal:
- Young Shil Park, Ph.D
-
Seoul, Coréia do Sul, 07804
- Recrutamento
- Ewha Womans University Medical Center
-
Contato:
- Site Contact
- Número de telefone: +82-2-6986-3100
- E-mail: anemia@khu.ac.kr
-
Investigador principal:
- Jae-joon Han
-
Ulsan, Coréia do Sul, 44033
- Recrutamento
- Ulsan University Hospital
-
Investigador principal:
- Yoo Jin Lee
-
Contato:
- Site Contact
- Número de telefone: +82-52-250-7000
- E-mail: yjleeh@uuh.ulsan.kr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants with AHA who are receiving OBIZUR Injection or initiate OBIZUR Injection treatment for the first time will be enrolled.
Descrição
Inclusion Criteria:
- Participants with AHA.
- Participants who are determined to have the clinical need to receive Obizur treatment.
- Participants aged 18 years or older at time of initiation of Obizur treatment.
- Participants agreed to participate in the study and voluntarily signed the informed consent.
Exclusion Criteria:
- Participants with hypersensitivity to any of the components of this drug.
- Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
- Participants for whom Obizur treatment is contraindicated as per product label.
- Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: OTHER
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
All Participants
Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice. |
OBIZUR injection.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI)
Prazo: Up to 3 months
|
Number of participants with AEs, causality to AEs, SAEs and AESI will be reported. The investigator will assess the causal relationship (causality) between the medicinal product and the AE using his/her clinical expertise and judgment. |
Up to 3 months
|
|
Number of Participants With Expected/Unexpected AEs and SAEs
Prazo: Up to 3 months
|
Unexpected AE is defined as AE that differs from the information in the product label in nature, severity, specificity, or outcome. |
Up to 3 months
|
|
Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRs
Prazo: Up to 3 months
|
An ADR refers to any undesirable and unintended reaction which occurs during or following the administration of the drug, and in which a causal relationship with the drug cannot be ruled out. In the event that a causal relationship with the drug remains unknown amongst reported adverse events, such reaction shall be considered an adverse drug reaction. Serious ADR means noxious or unintended response to a drug that occurs at any dosage and that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death. Unexpected ADRs is defined as ADR that differs from the information in the product label in nature, severity, specificity, or outcome. |
Up to 3 months
|
|
Number of Participants With Special Situation Report (SSR)
Prazo: Up to 3 months
|
SSR include following events: Pregnancy: any case in which a pregnancy participant is exposed to a Takeda Product or in which a female participant or partner of a male participant becomes pregnant following Takeda product.; Breastfeeding: infant exposure from breast milk; Overdose: all information of any accidental or intentional overdose; Drug abuse, misuse or medication error: all information on medicinal product (MP) abuse, misuse of medication error (potential or actual); Suspected transmission of infectious agent: Suspected (in sense of confirmed or potential) transmission of infectious agent by a MP; Lack of efficacy of Takeda Product; accidental/occupational exposure; Use outside the terms of the marketing authorization, also known as "off-label" and "off-label use"; Use of falsified and counterfeit MP; Drug-drug and drug-food interactions; Inadvertent or accidental exposure with or without an AE; Unintended benefit. |
Up to 3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With Overall Bleeding Control
Prazo: Up to 3 months
|
Overall Bleeding Control will be determined as either bleeding stopped or did not stop. |
Up to 3 months
|
|
Time to Achieve Bleeding Control With OBIZUR Injection
Prazo: Up to 3 months
|
Time to achieve bleeding control will be assessed from initiation of OBIZUR Injection (start time) to the time to achieve bleeding control (stop time). |
Up to 3 months
|
|
Number of OBIZUR Injection Infusion Required to Achieve Bleeding Control
Prazo: Up to 3 months
|
Number of OBIZUR injection infusion required to achieve bleeding control will be reported. |
Up to 3 months
|
|
Dose of OBIZUR Required to Stop the Bleeding
Prazo: Up to 3 months
|
OBIZUR dose required to stop the bleeding will be reported. |
Up to 3 months
|
|
Percentage of Participants With Bleeding Events
Prazo: Up to 3 months
|
Bleeding events will be evaluated and reported as re-bleed, concurrent bleed and subsequent bleed. Re-bleed: if it occurs in the same anatomical location and within 72 hours of the resolution of the previous bleeding. Concurrent bleed: if it occurs at the same time (that is, during treatment or within 72 hours of resolution) as previous bleed but at a different anatomical location. Subsequent bleed: if it is a new bleed occurring 72 hours after the resolution of the previous bleed (either in the same anatomical location or in a new one). |
Up to 3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Study Director, Takeda
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TAK-672-4002
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Critérios de acesso de compartilhamento IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .